Olmesartan HCTZ 40/25 (Apo) TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: olmesartan + hydrochlorothiazide
Pack: Olmesartan HCTZ 40/25 (Apo) tablet, 30, blister pack
Brand name
(ARTG)
: APO-OLMESARTAN HCTZ 40/25 olmesartan medoxomil/hydrochlorothiazide 40/25 mg film coated tablets blister packDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Indicated for the treatment of hypertension.,Treatment should not be initiated with this fixed dose combination.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- 40/25 mg film coated tablets are yellow film coated, oval shaped, biconvex tablets debossed with L348 on one side and plain on the other side.
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Store in a Dry Place
- Shelf lifetime is 2 Years.
- Store below 25 degrees Celsius
- Store in a Dry Place
- Shelf lifetime is 2 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 30 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient olmesartan + hydrochlorothiazide
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
